SV2017005433A - Síntesis de copanlisib y su sal diclorhidrato - Google Patents

Síntesis de copanlisib y su sal diclorhidrato

Info

Publication number: SV2017005433A
Authority: SV; El Salvador
Prior art keywords: copanlisib; diclorhydrate; synthesis; salt; new
Prior art date: 2014-11-07

Application number

SV2017005433A

Other languages

English (en)

Spanish (es)

Inventor

Jan-Georg Peters

Philipp Rubenbauer

Daniel Götz

Danja Groβbach

Franz-Josef Mais

Heiko Schirmer

Maurus Marty

Juergen Stiehl

Kai Lovis

Martin Deyfried

Theodor Zweifel

Günter Weingärtner

Andreas Lender

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-07

Filing date

2017-05-05

Publication date

2018-04-30

2017-05-05 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2018-04-30 Publication of SV2017005433A publication Critical patent/SV2017005433A/es

Links

PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 title abstract 6
229950002550 copanlisib Drugs 0.000 title abstract 6
230000015572 biosynthetic process Effects 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SV2017005433A 2014-11-07 2017-05-05 Síntesis de copanlisib y su sal diclorhidrato SV2017005433A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14192203.9A EP3018127A1 (de)	2014-11-07	2014-11-07	Synthese von Copanlisib sowie dessen Dihydrochloridsalz

Publications (1)

Publication Number	Publication Date
SV2017005433A true SV2017005433A (es)	2018-04-30

Family

ID=51866061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SV2017005433A SV2017005433A (es)	2014-11-07	2017-05-05	Síntesis de copanlisib y su sal diclorhidrato

Country Status (46)

Country	Link
US (1)	US10494372B2 (de)
EP (2)	EP3018127A1 (de)
JP (1)	JP6691115B2 (de)
KR (1)	KR102566834B1 (de)
CN (1)	CN107278204B (de)
AR (1)	AR102570A1 (de)
AU (1)	AU2015341788B2 (de)
BR (1)	BR112017009470B1 (de)
CA (1)	CA2966800C (de)
CL (1)	CL2017001131A1 (de)
CO (1)	CO2017004532A2 (de)
CR (1)	CR20170184A (de)
CU (1)	CU24489B1 (de)
CY (1)	CY1121602T1 (de)
DK (1)	DK3215493T3 (de)
DO (1)	DOP2017000112A (de)
EA (1)	EA035558B1 (de)
EC (1)	ECSP17027755A (de)
ES (1)	ES2721778T3 (de)
HR (1)	HRP20190720T1 (de)
HU (1)	HUE042866T2 (de)
IL (1)	IL251874A0 (de)
JO (1)	JO3644B1 (de)
LT (1)	LT3215493T (de)
MA (1)	MA40895B1 (de)
ME (1)	ME03358B (de)
MX (1)	MX366904B (de)
MY (1)	MY189852A (de)
NI (1)	NI201700054A (de)
NZ (1)	NZ731287A (de)
PE (1)	PE20170897A1 (de)
PH (1)	PH12017500833A1 (de)
PL (1)	PL3215493T3 (de)
PT (1)	PT3215493T (de)
RS (1)	RS58579B1 (de)
SA (1)	SA517381462B1 (de)
SG (1)	SG11201703702RA (de)
SI (1)	SI3215493T1 (de)
SV (1)	SV2017005433A (de)
TN (1)	TN2017000179A1 (de)
TR (1)	TR201905217T4 (de)
TW (1)	TWI697495B (de)
UA (1)	UA122398C2 (de)
UY (1)	UY36392A (de)
WO (1)	WO2016071435A2 (de)
ZA (1)	ZA201703867B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2168583A1 (de)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
EP2508525A1 (de)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
UA119537C2 (uk)	2013-04-08	2019-07-10	Байєр Фарма Акцієнгезелльшафт	ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
CA2978830A1 (en)	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CA3016584A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
CA3037626A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors
WO2018215282A1 (en)	2017-05-26	2018-11-29	Bayer Pharma Aktiengesellschaft	Combination of bub1 and pi3k inhibitors
EP3645005A1 (de)	2017-06-28	2020-05-06	Bayer Consumer Care AG	Kombination eines pi3k-hemmers mit einem androgen-rezeptor-antagonisten
EP3498266A1 (de)	2017-12-15	2019-06-19	Bayer Consumer Care AG	Formulierungen von copanlisib
CN111278430A (zh)	2017-09-08	2020-06-12	拜耳制药股份公司	库潘尼西制剂
WO2023139125A1 (en)	2022-01-18	2023-07-27	Synthon B.V.	Improved process for preparation of copanlisib
WO2023218032A1 (en)	2022-05-13	2023-11-16	Synthon B.V.	Solid forms of copanlisib salts

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1003580A (en)	1910-08-10	1911-09-19	Remington Typewriter Co	Type-writing machine.
US6221877B1 (en) *	2000-04-12	2001-04-24	Regents Of The University Of California	Substituted 4-phthalimidocarboxanilides as inhibitors of purine salvage phosphoribosyltransferases
IT1319674B1 (it) *	2000-12-01	2003-10-23	Erregierre Spa	Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) *	2001-04-13	2003-12-11	Kaneka Corp	Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
EP1417204B1 (de) *	2001-08-15	2006-01-18	E. I. du Pont de Nemours and Company	Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge
AU2003293310B2 (en)	2002-09-30	2010-04-01	Bayer Intellectual Property Gmbh	Fused azole-pyrimidine derivatives
AR064106A1 (es) *	2006-12-05	2009-03-11	Bayer Schering Pharma Ag	Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP5620275B2 (ja) *	2008-01-14	2014-11-05	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
EP2168583A1 (de)	2008-09-24	2010-03-31	Bayer Schering Pharma Aktiengesellschaft	Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
EP2508525A1 (de) *	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
JO3733B1 (ar)	2011-04-05	2021-01-31	Bayer Ip Gmbh	استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
UA119537C2 (uk)	2013-04-08	2019-07-10	Байєр Фарма Акцієнгезелльшафт	ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
JP6499657B2 (ja)	2013-12-03	2019-04-10	バイエルファーマアクチエンゲゼルシャフト	Ｐｉ３ｋ阻害剤の組み合わせ
EP3018131A1 (de) *	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthese von Copanlisib sowie dessen Dihydrochloridsalz
CA2978830A1 (en)	2015-03-09	2016-09-15	Bayer Pharma Aktiengesellschaft	Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
JP2018512403A (ja)	2015-03-09	2018-05-17	バイエルファーマアクチエンゲゼルシャフト	置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
CA3012951A1 (en)	2016-02-01	2017-08-10	Bayer Pharma Aktiengesellschaft	Copanlisib biomarkers
EP3411497A1 (de)	2016-02-01	2018-12-12	Bayer Pharma Aktiengesellschaft	Copanlisib-biomarker
CA3016584A1 (en)	2016-03-08	2017-09-14	Bayer Pharma Aktiengesellschaft	2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
CA3037626A1 (en)	2016-09-23	2018-03-29	Bayer Pharma Aktiengesellschaft	Combination of pi3k-inhibitors

2014
- 2014-11-07 EP EP14192203.9A patent/EP3018127A1/de not_active Withdrawn
2015
- 2015-11-04 JO JOP/2015/0274A patent/JO3644B1/ar active
- 2015-11-05 MA MA40895A patent/MA40895B1/fr unknown
- 2015-11-05 WO PCT/EP2015/075789 patent/WO2016071435A2/en not_active Ceased
- 2015-11-05 ME MEP-2019-107A patent/ME03358B/de unknown
- 2015-11-05 EA EA201790983A patent/EA035558B1/ru not_active IP Right Cessation
- 2015-11-05 SG SG11201703702RA patent/SG11201703702RA/en unknown
- 2015-11-05 MX MX2017005893A patent/MX366904B/es active IP Right Grant
- 2015-11-05 PL PL15790150T patent/PL3215493T3/pl unknown
- 2015-11-05 CA CA2966800A patent/CA2966800C/en active Active
- 2015-11-05 HR HRP20190720TT patent/HRP20190720T1/hr unknown
- 2015-11-05 ES ES15790150T patent/ES2721778T3/es active Active
- 2015-11-05 KR KR1020177014992A patent/KR102566834B1/ko active Active
- 2015-11-05 BR BR112017009470-3A patent/BR112017009470B1/pt not_active IP Right Cessation
- 2015-11-05 RS RS20190453A patent/RS58579B1/sr unknown
- 2015-11-05 UY UY0001036392A patent/UY36392A/es not_active Application Discontinuation
- 2015-11-05 AU AU2015341788A patent/AU2015341788B2/en not_active Ceased
- 2015-11-05 PT PT15790150T patent/PT3215493T/pt unknown
- 2015-11-05 TR TR2019/05217T patent/TR201905217T4/tr unknown
- 2015-11-05 PE PE2017000818A patent/PE20170897A1/es unknown
- 2015-11-05 DK DK15790150.5T patent/DK3215493T3/da active
- 2015-11-05 CN CN201580072735.8A patent/CN107278204B/zh not_active Expired - Fee Related
- 2015-11-05 TN TN2017000179A patent/TN2017000179A1/en unknown
- 2015-11-05 US US15/524,581 patent/US10494372B2/en active Active
- 2015-11-05 MY MYPI2017701550A patent/MY189852A/en unknown
- 2015-11-05 SI SI201530695T patent/SI3215493T1/sl unknown
- 2015-11-05 HU HUE15790150A patent/HUE042866T2/hu unknown
- 2015-11-05 JP JP2017523881A patent/JP6691115B2/ja not_active Expired - Fee Related
- 2015-11-05 UA UAA201705433A patent/UA122398C2/uk unknown
- 2015-11-05 CR CR20170184A patent/CR20170184A/es unknown
- 2015-11-05 CU CU2017000061A patent/CU24489B1/es unknown
- 2015-11-05 LT LTEP15790150.5T patent/LT3215493T/lt unknown
- 2015-11-05 EP EP15790150.5A patent/EP3215493B1/de active Active
- 2015-11-05 NZ NZ731287A patent/NZ731287A/en not_active IP Right Cessation
- 2015-11-06 AR ARP150103619A patent/AR102570A1/es unknown
- 2015-11-06 TW TW104136742A patent/TWI697495B/zh not_active IP Right Cessation
2017
- 2017-04-24 IL IL251874A patent/IL251874A0/en active IP Right Grant
- 2017-05-04 PH PH12017500833A patent/PH12017500833A1/en unknown
- 2017-05-04 SA SA517381462A patent/SA517381462B1/ar unknown
- 2017-05-05 SV SV2017005433A patent/SV2017005433A/es unknown
- 2017-05-05 CO CONC2017/0004532A patent/CO2017004532A2/es unknown
- 2017-05-05 EC ECIEPI201727755A patent/ECSP17027755A/es unknown
- 2017-05-05 DO DO2017000112A patent/DOP2017000112A/es unknown
- 2017-05-05 CL CL2017001131A patent/CL2017001131A1/es unknown
- 2017-05-05 NI NI201700054A patent/NI201700054A/es unknown
- 2017-06-06 ZA ZA2017/03867A patent/ZA201703867B/en unknown
2019
- 2019-04-23 CY CY20191100444T patent/CY1121602T1/el unknown

Also Published As

Publication number	Publication date
MA40895A (fr)	2017-09-13
MA40895B1 (fr)	2019-07-31
EA035558B1 (ru)	2020-07-07
EP3215493B1 (de)	2019-01-23
HUE042866T2 (hu)	2019-07-29
AR102570A1 (es)	2017-03-08
HRP20190720T1 (hr)	2019-06-14
PE20170897A1 (es)	2017-07-12
NI201700054A (es)	2017-07-17
PH12017500833A1 (en)	2017-10-18
TR201905217T4 (tr)	2019-05-21
HK1245774A1 (zh)	2018-08-31
NZ731287A (en)	2023-01-27
CA2966800A1 (en)	2016-05-12
DK3215493T3 (da)	2019-05-06
WO2016071435A3 (en)	2016-06-30
CY1121602T1 (el)	2020-05-29
UA122398C2 (uk)	2020-11-10
ME03358B (de)	2019-10-20
CN107278204B (zh)	2019-12-17
KR20170082563A (ko)	2017-07-14
SA517381462B1 (ar)	2021-01-25
CO2017004532A2 (es)	2017-07-19
TN2017000179A1 (en)	2018-10-19
CU20170061A7 (es)	2017-10-05
PT3215493T (pt)	2019-05-21
AU2015341788A1 (en)	2017-05-18
AU2015341788B2 (en)	2020-01-16
US20180282337A1 (en)	2018-10-04
MX366904B (es)	2019-07-30
BR112017009470B1 (pt)	2022-11-01
CU24489B1 (es)	2020-12-17
CN107278204A (zh)	2017-10-20
CL2017001131A1 (es)	2018-01-19
EP3018127A1 (de)	2016-05-11
BR112017009470A2 (en)	2018-01-02
SG11201703702RA (en)	2017-06-29
JO3644B1 (ar)	2020-08-27
MY189852A (en)	2022-03-14
ZA201703867B (en)	2019-07-31
EP3215493A2 (de)	2017-09-13
CR20170184A (es)	2017-06-20
US10494372B2 (en)	2019-12-03
IL251874A0 (en)	2017-06-29
ECSP17027755A (es)	2017-06-30
MX2017005893A (es)	2017-06-30
KR102566834B1 (ko)	2023-08-16
JP6691115B2 (ja)	2020-04-28
ES2721778T3 (es)	2019-08-05
SI3215493T1 (sl)	2019-05-31
DOP2017000112A (es)	2017-06-15
CA2966800C (en)	2023-02-21
PL3215493T3 (pl)	2019-07-31
UY36392A (es)	2016-06-30
TWI697495B (zh)	2020-07-01
LT3215493T (lt)	2019-04-25
JP2017534631A (ja)	2017-11-24
RS58579B1 (sr)	2019-05-31
WO2016071435A2 (en)	2016-05-12
TW201625634A (zh)	2016-07-16
EA201790983A1 (ru)	2017-10-31

Publication	Publication Date	Title
CL2017001131A1 (es)	2018-01-19	Síntesis de copanlisib y su sal diclorhidrato
AR132627A2 (es)	2025-07-16	Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
CL2016001871A1 (es)	2017-05-19	Anticuerpos humanos para pd-1
MX393838B (es)	2025-03-21	Uso de compuestos heterociclicos para controlar nematodos.
CL2016002055A1 (es)	2017-07-14	Uso de compuestos 3-isoxazolidinonas como herbicidas selectivos
CL2017001130A1 (es)	2018-01-19	Síntesis de copanlisib y su sal diclorhidrato
BR112016025427A2 (pt)	2017-08-15	processos de preparação de um inibidor de jak1 e formas do mesmo
TWD171885S (zh)	2015-11-21	汽車用水箱護罩桿
EA201692219A1 (ru)	2017-05-31	Способы получения противовирусных соединений
ECSP16061758A (es)	2018-02-28	Moduladores de tetrahidropiridopirazinas de gpr6
EA202092609A1 (ru)	2021-10-29	Антитела к cd38 для лечения острого миелолейкоза
CR20160098A (es)	2016-07-11	Polimorfo de los inhibidores de la syk
ES2897914T8 (es)	2022-03-17	Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos
BR112017013767A2 (pt)	2018-03-13	uso de picolinamidas como fungicidas
BR112016017402A2 (pt)	2017-10-17	fusões anti-pcsk9~glp-1 e métodos para uso
MX2016014765A (es)	2017-03-06	Incremento del rendimiento utilizando soforolipidos.
EA201691367A1 (ru)	2016-10-31	Кристаллические формы дималеата афатиниба
BR112017001391A2 (pt)	2017-11-21	componentes para o fusionamento de corpos vertebrais
MX2017008097A (es)	2018-01-09	Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
BR112017013286A2 (pt)	2018-03-06	composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112016029510A2 (pt)	2017-08-22	métodos para a preparação de um composto, e, composto intermediário.
MX369857B (es)	2019-11-25	Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
BR112017008854A2 (pt)	2017-12-19	partículas de cadotrila
CO2017010143A2 (es)	2018-02-28	Procesos para preparar fluorocetólidos
EA201690263A1 (ru)	2016-06-30	Улучшенные способы получения перампанеля